Epidemiology of Progressive Supranuclear Palsy: Real World Data from the Second Largest Health Plan in Israel

Yael Barer*, Gabriel Chodick, Raanan Cohen, Meital Grabarnik-John, Xiaolan Ye, Jorge Zamudio, Tanya Gurevich

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Progressive supranuclear palsy (PSP) is a rare and fatal neurodegenerative movement disorder and no disease modifying therapy (DMT) is currently available. This study aims to assess the epidemiology of PSP in Israel and to describe its clinical features. This retrospective analysis identified patients with PSP between 2000 and 2018 over the age of 40 years at first diagnosis (index date). We identified 209 patients with ≥1 diagnosis of PSP. Of those, 88 patients satisfied the inclusion criteria with a mean age at diagnosis of 72 years (SD = 8) and 53% were female. The 2018 prevalence and incidence rates were 5.3 and 1 per 100,000 persons, respectively. Median survival time was 4.9 years (95% CI 3.6–6.1) and median time from initial symptom to diagnosis was 4.2 years. The most common misdiagnoses were Parkinson’s disease, cognitive disorder and depression. The present study demonstrates that the clinic-epidemiological features of PSP in Israel are similar to PSP worldwide. In light of PSP’s rarity, investigation of PSP cohorts in different countries may create a proper platform for upcoming DMT trials.

Original languageEnglish
Article number1126
JournalBrain Sciences
Volume12
Issue number9
DOIs
StatePublished - Sep 2022

Funding

FundersFunder number
AbbVie

    Keywords

    • clinical features
    • future disease modifying trials
    • incidence
    • natural history
    • prevalence
    • progressive supranuclear palsy
    • real world data

    Fingerprint

    Dive into the research topics of 'Epidemiology of Progressive Supranuclear Palsy: Real World Data from the Second Largest Health Plan in Israel'. Together they form a unique fingerprint.

    Cite this